A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I Study Group.

Détails

Demande d'une copieDemande d'une copie
ID Serval
serval:BIB_754C6766BB0B
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Production externe
Titre
A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I Study Group.
Périodique
Neurology
Auteur⸱e⸱s
Borasio G.D., Robberecht W., Leigh P.N., Emile J., Guiloff R.J., Jerusalem F., Silani V., Vos P.E., Wokke J.H., Dobbins T.
ISSN
0028-3878 (Print)
ISSN-L
0028-3878
Statut éditorial
Publié
Date de publication
1998
Volume
51
Numéro
2
Pages
583-586
Langue
anglais
Notes
Publication types: Clinical Trial ; Journal Article ; Multicenter Study ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov'tPublication Status: ppublish
Résumé
To test the safety and efficacy of recombinant human insulin-like growth factor-I (rhIGF-I) in ALS, 183 patients from eight European centers were randomized to receive double-blind placebo (n = 59) or rhIGF-I 0.1 mg/kg/day (n = 124) subcutaneously for 9 months. At study completion, the primary efficacy outcome measure (change in disease progression as assessed by the Appel ALS rating scale) showed no significant difference between treatment groups. RhIGF-I appeared to be safe and well-tolerated.
Mots-clé
Adult, Amyotrophic Lateral Sclerosis/drug therapy, Double-Blind Method, Europe, Humans, Insulin-Like Growth Factor I/therapeutic use, Recombinant Proteins/therapeutic use
Pubmed
9710040
Web of science
000075387400048
Création de la notice
13/01/2014 18:01
Dernière modification de la notice
20/08/2019 15:32
Données d'usage